NVNO

enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.

Wall Street analysts forecast NVNO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVNO is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

enVVeno Medical Corp revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

enVVeno Medical Corp. EPS for the last quarter amounts to -0.23 USD, decreased -34.29 % YoY.

enVVeno Medical Corp (NVNO) has 37 emplpoyees as of December 15 2025.

Today NVNO has the market capitalization of 6.62M USD.